Skip to main content
. 2024 May 24;15:1403771. doi: 10.3389/fimmu.2024.1403771

Figure 2.

Figure 2

Forest plot illustrating the impact of myeloid-derived suppressor cell levels on progression-free survival in patients receiving immune checkpoint inhibitor therapy.